Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-07-19
- Target Recruit Count
- 59
- Registration Number
- NCT05846750
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tian, China
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
- Conditions
- Multiple Myeloma
- Interventions
- Biological: anti-BCMA CAR-T
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2024-07-25
- Target Recruit Count
- 20
- Registration Number
- NCT05846737
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
- Conditions
- Follicular Lymphoma
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-23
- Target Recruit Count
- 50
- Registration Number
- NCT05846763
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin, China
Efficacy of Daratumumab to Overcome Platelet Transfusion Refractoriness in Patients with Aplastic Anemia
- Conditions
- Aplastic AnemiaPlatelet Transfusion Refractoriness
- Interventions
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2025-01-03
- Target Recruit Count
- 10
- Registration Number
- NCT05832216
- Locations
- 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China
LILRB4 STAR-T Cell Therapy for Monocytic Leukemia
- Conditions
- Chronic Myelomonocytic LeukemiaAcute Myelogenous Leukemia
- Interventions
- Biological: LILRB4 STAR-T cells injection
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2023-02-22
- Target Recruit Count
- 10
- Registration Number
- NCT05739409
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation
- Conditions
- Hematological DiseaseAllogeneic Hematopoietic Stem Cell Transplantation
- Interventions
- Other: placebo
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2023-02-14
- Target Recruit Count
- 78
- Registration Number
- NCT05727917
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Avatrombopag Combined With IST as First-line Treatment for SAA
- First Posted Date
- 2023-02-09
- Last Posted Date
- 2023-02-09
- Target Recruit Count
- 53
- Registration Number
- NCT05720234
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
- Conditions
- Primary Immune Thrombocytopenia (ITP)
- Interventions
- Drug: TPO-RAsDrug: TPO-RAs combining anti-CD 20 monoclonal antibody
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-07-30
- Target Recruit Count
- 166
- Registration Number
- NCT05718856
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2025-02-21
- Target Recruit Count
- 9
- Registration Number
- NCT05709288
- Locations
- 🇨🇳
Institute of haematology and Blood diseases hospital, Tianjin, Tianjin, China
A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2025-02-24
- Target Recruit Count
- 22
- Registration Number
- NCT05694767
- Locations
- 🇨🇳
Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin, Tianjin, China